Review Articles
Pembrolizumab (Anti-PD-1) Immunotherapy in Malignant Pleural Mesothelioma: A Systematic Review of the Current Literature
Published:
July 27, 2023
Abstract
Introduction
Malignant pleural mesothelioma is an infrequent and aggressive type of cancer that is difficult to treat, and standard therapies have shown limited effectiveness. There have been recent advances in the development of targeted therapies for malignant pleural mesothelioma, including immunotherapy with pembrolizumab.
Methods
This is a systematic review of the current role of pembrolizumab in the treatment of this disease. A systematic search was conducted through the databases and search engines. The eligible studies to be included were those that primarily focused on the outcomes of treating this disease with pembrolizumab, regardless of study design, line of therapy, mode of therapy, and ECOG performance status.
Results
After the initial and full-text screenings, 15 studies were reviewed. The number of cases was 454 with a mean age of 68.13 years, of which males (79.7%) were the predominant gender. Most of the cases were affected by epithelioid mesothelioma (76.7%). Pembrolizumab had been used as the first line of treatment in 62 (13.7%) cases. In 92.73% of cases, the therapy mode was pembrolizumab monotherapy. A total of 68 different adverse events were recorded. The most commonly associated adverse events were fatigue (14.8%), pruritis/rash (13.7%), and diarrhea (9.7%). Two patients died due to adverse events. The overall objective response was 17.8%, stable disease was 35.7%, progression-free survival was about 47.6% with a mean of 4.73 months, and 117 cases (25.8%) could reach treatment-related survival.
Conclusion
Pembrolizumab can serve as a viable alternative in the management of malignant pleural mesothelioma, offering satisfactory outcomes and acceptable safety profiles.
References
- Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. The Lancet Oncology. 2017 ;18(5):623-30. doi:10.1016/S1470-2045(17)30169-9
- Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56-61. doi:10.1126/science.aaa8172
- Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. New England Journal of Medicine. 2015;372(21):2018-28. doi:10.1056/NEJMoa1507643
- Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. British journal of cancer. 2018;119(2):153-9. doi:10.1038/s41416-018-0131-9
- Maly J, Alinari L. Pembrolizumab in classical Hodgkin's lymphoma. European journal of haematology. 2016;97(3):219-27. doi:10.1111/ejh.12770
- Bellmunt J, De Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. New England Journal of Medicine. 2017;376(11):1015-26. doi:10.1056/NEJMoa1613683
- Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. New England Journal of Medicine. 2015;372(26):2521-32. doi:10.1056/NEJMoa1503093
- Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. The Lancet. 2018 ;392(10142):123-33. doi:10.1016/S0140-6736(18)31257-1
- Finn RS, Ryoo BY, Merle P, Bouattour M, Lim HY, Breder V, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. 2019; 38(3): 193-202. doi:10.1200/JCO.19
- Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New England Journal of Medicine. 2019 ;380(12):1116-27. doi:10.1056/NEJMoa1816714
- Robinson BW, Lake RA. Advances in malignant mesothelioma. New England Journal of Medicine. 2005;353(15):1591-603. doi:10.1056/NEJMra050152
- Ismail-Khan R, Robinson LA, Williams Jr CC, Garrett CR, Bepler G, Simon GR. Malignant pleural mesothelioma: a comprehensive review. Cancer control. 2006;13(4):255-63. doi:N/A
- Gray SG. Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma. BMC Pulmonary Medicine. 2021;21(1):1-24. doi:10.1186/s12890-021-01513-7
- Ahmadzada T, Cooper WA, Holmes M, Mahar A, Westman H, Gill AJ, et al. Retrospective evaluation of the use of Pembrolizumab in malignant mesothelioma in a real-world Australian population. JTO Clinical and Research Reports. 2020;1(4):100075. doi:10.1016/j.jtocrr.2020.100075
- Muhialdeen AS, Ahmed JO, Baba HO, Abdullah IY, Hassan HA, Najar KA, et al. Kscien’s List; A New Strategy to Discourage Predatory Journals and Publishers (Second Version).Barw Medical Journal. 2023; 1(1);30-32. doi:N/A
- Popat S, Curioni-Fontecedro A, Dafni U, Shah R, O'Brien M, Pope A, et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Annals of Oncology. 2020;31(12):1734-45. doi:10.1016/j.annonc.2020.09.009
- Danlos FX, Texier M, Job B, Mouraud S, Cassard L, Baldini C, et al. Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti–PD-1+ Antiangiogenesis in Malignant Pleural Mesothelioma. Cancer Discovery. 2023;13(4):858-79. doi:10.1158/2159-8290.CD-22-0886
- Yap TA, Nakagawa K, Fujimoto N, Kuribayashi K, Guren TK, Calabrò L, et al. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. The Lancet Respiratory Medicine. 2021;9(6):613-21. doi:10.1016/S2213-2600(20)30515-4
- Metaxas Y, Rivalland G, Mauti LA, Klingbiel D, Kao S, Schmid S, et al. Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. Journal of Thoracic Oncology. 2018 ;13(11):1784-91. doi:10.1016/j.jtho.2018.08.007
- Shalata W, Iraqi M, Bhattacharya B, Fuchs V, Roisman LC, Cohen AY, et al. Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients With Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma). Cancers. 2021;13(14):3630. doi:10.3390/cancers13143630
- Zhou M, Joshi N, Raj KP, Wakelee H, Neal JW. PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review. Clinical Lung Cancer. 2021;22(3):e329-35. doi:10.1016/j.cllc.2020.05.012
- Bickel A, Koneth I, Enzler-Tschudy A, Neuweiler J, Flatz L, Früh M. Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma. BMC cancer. 2016; 16:1-3. doi:10.1186/s12885-016-2718-y
- Hearon BF, Redelman KN, Elhomsy GC, Moore Jr DF. Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy. Case Reports in Oncology. 2020;13(3):1483-9. doi:10.1159/000512013
- Mampuya WA, Bouchaab H, Schaefer N, Kinj R, La Rosa S, Letovanec I, et al. Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab. Clinical and Translational Radiation Oncology. 2021; 27:85-8. doi:10.1016/j.ctro.2020.12.006
- Minchom A, Yuan W, Crespo M, Gurel B, Figueiredo I, Wotherspoon A, et al. Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab. Journal for Immunotherapy of Cancer. 2020;8(1): e000713. doi:10.1136/jitc-2020-000713
- Rittberg R, Chan E, Yip S, Alex D, Ho C, Chan EK. Radiation Induced Abscopal Effect in a Patient With Malignant Pleural Mesothelioma on Pembrolizumab. Cureus. 2022;14(2): e22159. doi:10.7759/cureus.22159
- Baldauf MC, Kapauer M, Joerger M, Flatz L, Rodriguez R, Frank S, et al. Pembrolizumab-Associated CD8+ Vasculitic Mononeuritis Multiplex in a Patient with Mesothelioma. Neurology® Neuroimmunology & Neuroinflammation. 2021;8(4): e993. doi:10.1212/NXI.0000000000000993
- Schiopu SR, Käsmann L, Schönermarck U, Fischereder M, Grabmaier U, Manapov F, et al. Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy—case report. Translational Lung Cancer Research. 2021;10(2):1039- 1046. doi:10.21037/tlcr-20-1095
- Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of clinical oncology. 2003;21(14):2636-44. doi:10.1200/jco.2003.11.136
- Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. The Lancet. 2016 ;387(10026):1405-14. doi:10.1016/S0140-6736(15)01238-6
- Grosso F, Steele N, Novello S, Nowak AK, Popat S, Greillier L, et al. Nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial. Journal of Clinical Oncology. 2017;35(31):3591-600. doi:10.1200/JCO.2017.72.9012
- Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. The Lancet Respiratory Medicine. 2019;7(7):569-80. doi:10.1016/S2213-2600(19)30139-0
- Desai A, Karrison T, Rose B, Tan Y, Hill B, Pemberton E, et al. OA08. 03 phase II trial of pembrolizumab (NCT02399371) in previously-treated malignant mesothelioma (MM): final analysis. Journal of Thoracic Oncology. 2018;13(10):S339. doi:10.1016/j.jtho.2018.08.277
- Forde PM, Sun Z, Anagnostou V, Kindler HL, Purcell WT, Goulart BH, et al. PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC study. Journal of Clinical Oncology. 2020;38(15):9003. doi:10.1200/JCO.2020.38.15_suppl.9003
- Kao SC, Cheng YY, Williams M, Kirschner MB, Madore J, Lum T, et al. Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma. Journal of Thoracic Oncology. 2017;12(9):1421-33. doi:1016/j.jtho.2017.05.024
- Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, et al. Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT) Nivolumab In Japanese Patients With Advanced/Metastatic MPM. Clinical Cancer Research. 2019;25(18):5485-92. doi:10.1158/1078-0432.CCR-19-0103
- Lopci E, Zucali PA, Ceresoli GL, Perrino M, Giordano L, Gianoncelli L, et al. Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma. European journal of nuclear medicine and molecular imaging. 2015; 42:667-75. doi:10.1007/s00259-014-2960-y
Keywords
Copyright (c) 2023 Barw Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.